Dana-Farber Cancer Institute Leads Clinical Trial of First-in-Class Imaging Agent

Jul 25, 2019 | CD8+ T-cells, Dana-Farber Cancer Institute, Immuno-oncology

Dana-Farber Cancer Institute Leads Clinical Trial of First-in-Class Imaging Agent

ImaginAB Inc., a Los Angeles-based, immune-oncology imaging company focused on offering actionable insight into patient selection and treatment for cancer immunotherapy, enabling precision medicine to ink a deal with Dana-Farber Cancer Institute, one of the world’s leading research cancer centers, for a first-in-class imaging agent clinical trial.

ImaginAB inc., a clinical-stage, immune-oncology imaging company, announced their partnership with Dana-Farber Cancer Institute to lead a study of its lead product, CD8 tracer Zr-Df-IAB22M2C, a first-in-class imaging agent that visualizes the immune system using a non-invasive, whole-body in vivo PET imaging of CD8 T cells. ImaginAB has developed its ‘Mindbody’ platform for targeting and visualizing CD8+ T-cells to provide highly specific, quantitative assessment of the immunological status of each cancer lesion within a patient, potentially enabling treatment to be tailored quickly and specifically to the needs of the patient.

Dana-Farber Cancer Institute is an Active Clinical Site for ImaginAb

Annick Van Abbeele, MD, Chairman Emeritus of the Department of Imaging at Dana-Farber Cancer Institute, is the study’s principal investigator. She will investigate the utility of Zr-Df-IAB22M2C to image Cd8 T cells prior to baseline.

The Study

The study will enroll metastatic cancer patients and will study the correlation of imaging signals observed using ImaginAb’s CD8 T cell ImmunoPET imaging agent, standard-of-care scans, and immunohistochemistry analysis of CD8 in biopsied tissues. This trail will also measure changes in CD8+ T-cell distribution before and after immune-oncology therapies.

ImaginAB

ImaginAb Inc. is an immuno-oncology imaging company focused on providing actionable insight into patient selection and treatment progress for cancer immunotherapy, enabling precision medicine. ImaginAb engineers antibody fragments called minibodies that maintain the exquisite specificity of full-length antibodies while remaining inert in the body. Used with widely available PET scan technology, these novel minibodies illuminate high-value molecular targets, providing physicians with a whole-body picture of immune activity. ImaginAb is also developing a pipeline for other targets in oncology. ImaginAb’s products have the potential to improve patient care and lower healthcare costs. The Company is backed by top-tier venture capital firms and strategic corporate firms, including The Parker Institute for Cancer Immunotherapy, Nextech Invest, Adage Capital, The Cycad Group, Merck (MSD) Pharma, Novartis Bioventures and Jim Pallotta of the Raptor Group.

 Lead Research/Investigator

Annick Van Abbeele, MD, Chairman Emeritus, Department of Imaging at Dana-Farber Cancer Institute, is the study’s principal investigator. She will investigate the utility of Zr-Df-IAB22M2C to image Cd8 T cells prior to baseline.

0 Comments

Pin It on Pinterest